Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Fiche publication
Date publication
avril 2021
Journal
European heart journal. Cardiovascular pharmacotherapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, González A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F
Lien Pubmed
Résumé
Uncontrolled blood pressure (BP) increases the risk of developing heart failure (HF). The effect of spironolactone on BP of patients at risk of developing HF is yet to be determined.
Mots clés
cardiovascular risk, hypertension, renin, spironolactone
Référence
Eur Heart J Cardiovasc Pharmacother. 2021 Apr 2;: